BOSTON and MUNICH, Germany--(BUSINESS WIRE)--Oct. 5, 2005--TVM, one of the leading life sciences and information technology venture capital firms in Europe and the United States, today announced the closing of its latest life sciences fund, TVM Life Science Ventures VI (TVM LSV VI). Committed capital totaled $290.8 million (EUR 240.3 million) and was raised from a broad mix of investors, including lead investors European Investment Fund (ERP-EIF Fund of Funds) and AlpInvest. About 20 other investors from Europe, the United States and Asia have invested in the new TVM fund, including KfWBankengruppe (Germany), Skandia Liv Asset Management (Sweden); Temasek Holdings Pte Ltd. (Singapore); Development Fund, Taiwan government’s economic investment catalyst; and Quintiles Transnational Corp., the world’s largest pharmaceutical services organization. Genzyme Corporation, and Biogen Idec, two of the most prominent global biotech companies headquartered in the U.S., also invested in TVM LSV VI.
